stars 1 stars 2 stars 3

Anokion SA is a Swiss biotechnology company that aims to make a meaningful difference in the lives of patients suffering from autoimmune diseases by restoring normal immune tolerance. The company is focused on both prevalent and rare autoimmune diseases, including celiac disease, multiple sclerosis and type 1 diabetes. Anokion’s distinct approach leverages the company’s immune-based platform, which targets natural pathways in the liver to restore immune tolerance and address the underlying cause of autoimmune disease.

Anokion Questions

The Anokion annual revenue was $10.4 million in 2026.

Virginia Isak is the Director Clinical Operations (Immunology) of Anokion.

4 people are employed at Anokion.

Anokion is based in Cambridge, Massachusetts.

The NAICS codes for Anokion are [541, 541714, 54, 6215, 62, 5417, 621, 54171, 62151].

The SIC codes for Anokion are [87, 873].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users